Q-linea AB · OMXSTO:QLINEA
Q-linea AB — Shareholder Meeting (2022)
19 slides from Q-linea AB's shareholder meeting presentation, 2022
Slide 1: Presentation for AGM 2022
Presentation for AGM 2022 Jonas Jarvius, CEO STRICTLY PRIVATE AND CONFIDENTIAL
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea 2021
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 2021 Q-linea is developing disruptive solutions for faster infectious disease Lead product ASTar® diagnostics, first product targeting sepsis Introduction to the company 146 beginning of 2021 to 173 employees & consultant
Slide 4: Q-linea facilities & staff
Q-linea facilities & staff Consumable production and Instrument release Headquarter, management, finance & R&D Commercial, training & demo Research, development & production in Uppsala Sweden 4
Slide 5: Why is improved infectious disease diagnostics important?
Why is improved infectious disease diagnostics important? Sepsis AMR Antimicrobial Resistance Leading cause of death in U.S. hospitals1) Has been presented as #1 hospitalization cost in the US with over $24bn “The biggest threat to mankind” yearly3) Rapid diagnostics would reduce Kills >500,000 peop
Slide 6: An overview of 2021, accomplishments & achievements
An overview of 2021, accomplishments & achievements Q1 Q2 ASTar receives CE-IVD approval for first product Presented strong interim results from the CE-IVD study Gram negative bacteria in BSI Excellent data Essential agreement (EA) over 94%, Broad coverage Categorical agreement (CA) over 97 %, Stron
Slide 7: ASTar workflow vs current workflow
Up to 48 hours faster actionable results Transportation of blood culture from patient to laboratory: 1 – 24+ hours DAY 1 DAY 2 DAY 3 DAY 4 Plates are streaked CURRENT WORKFLOW Gram Susceptibility Patient to perform a Colony blood draw stain clean culture selection Determination (AST) Optimized Time
Slide 8: Health economic benefits of 24 hour faster diagnostics
Health economic benefits of 24 hour faster diagnostics Less pressure for Cost savings Lower mortality resistance and superinfections Up to 25% Up to 40% ~$2,500 – $20,000 reduction of C. difficile lower mortality rates1) cost savings per patient3) infections2) ASTar can provide up to 48 hours faster
Slide 9: ASTar makes a difference in patient outcome
ASTar makes a difference in patient outcome Patient-case from first commercial evaluation in Sweden ASTar results Patient • ASTar results at least 18 h earlier than Std-AST. • Man, 64, surgery department • MIC results from 13 additional antibiotics • Empiric treatment Piperacillin/tazobactam • Resis
Slide 10: ASTar – a platform designed to save lifetimes
ASTar – a platform designed to save lifetimes Developed together with our future customers Easy to use Comprehensive • Fully automated • Large antibiotic panel • ~2 min hands-on time • Long concentration • Load-and go workflow ranges • Fastidious and non- fastidious bacteria Fast • Support additiona
Slide 11: Easy to use
Easy to use User friendly & 24/7 availability ASTar enables anyone at the lab to load sample anytime and enables lab personnel to do more in less time Click “start” Scan barcode Add sample Load AST disc Add sample barcode Click “Start run” Source: Company information and webpage 11
Slide 12: ASTar provides excellent performance
ASTar provides excellent performance Broadest panel enabling actionable results Excellent and accurate data from the CE-IVD clinical study FDA and ISO requirements1,2) The ASTar® Instrument and ASTar® BC G- Kit offer the Essential agreement = Same MIC value as reference broadest combination of antim
Slide 13: High throughput and flexible solution
High throughput and flexible solution High throughput & flexible Our ambition was the most user friendly and capable system Up to 12 patient samples in parallel = Fully automatic Semi automatic Consumables stored at room temp and a small insert at -20°C. Compatible with small and large (e.g. urine)
Slide 14: Excellent results from extensive commercial evaluation
Excellent results from extensive commercial evaluation ASTar performed very well with great customer feedback Evaluation performed by Thermo Fisher Scientific™ with support from Q-linea Customer sites performed ASTar testing on G- BC+ patient samples in parallel to their current testing Almost 500 d
Slide 15: 2022 so far
2022 so far ECCMID 2022, Lisbon The interest in ASTar and other Q-linea products in developing was very strong Both the Q-linea and Thermo Fisher Scientific booth were fully occupied with demonstrations of ASTar A strong list of leads for both companies to follow up after ECCMID Positive response on
Slide 16: ASTar – breakthrough technology
ASTar – breakthrough technology ASTar classified as a breakthrough device by the FDA Benefit for patients US market approaching • “breakthrough device” • Breakthrough device can be assigned to designation enables products that are prioritized regulatory considered to provide a review by the FDA more
Slide 17: Unique technology enables disruptive expansion pipeline & opportunities
Unique technology enables disruptive expansion pipeline & opportunities Blood culturing Identification Susceptibility testing Mass spec Molecular TRADITIONAL TECHNOLOGY Podler® ASTrID® ASTar ASTrea™ Highly multiplexed ® Q-LINEA TECHNOLOGY Portable blood culturing and readout. molecular ID analysis E
Slide 18: The effects of the Corona pandemic on Q-linea
The effects of the Corona pandemic on Q-linea Moving back to normal operation Finally, we are now all moving back to the new normal after the pandemic Our conclusion is that Q-linea and its personnel has managed the pandemic in a good way No identified spread within the company Rapid follow up and i
Slide 19: Full speed ahead with commercial activities
Full speed ahead with commercial activities Strong interest from customers to evaluate ASTar Ongoing activities • Pre-market activities ongoing at full speed • Training of personnel ongoing • Marketing material in final preparation Staged launch for long-term success • First evaluation customers in